Galitzer summarizes his holistic treatment philosophy with the FIGHT EM strategy, urging for a comprehensive approach that addresses nutrition, infections, geopathic stress, hormones, toxins, and emotional health for overall cancer management and prevention
The first ADC Mylotarg was withdrawn from the market in 2010 due to toxic effects but was subsequently re-approved in 2017 after specifying the patient population and adjusting its administration regimen
PMC 2390769
This response was more limited to the gut, so may have helped more in people with gastrointestinal issues like irritable bowel syndrome and Crohns
For the full profile and vendor pricing, see our PDA peptide page
Zolghadri S, Bahrami A, Hassan Khan MT, Munoz-Munoz J, Garcia-Molina F, Garcia-Canovas F, Saboury AA (2019) A comprehensive review on tyrosinase inhibitors